HBI Deals+Insights / Digital and AI
The quick rise of health apps has meant processes for approval and reimbursement have largely replicated ones for bringing new drugs to market. That is now starting to change, with many of the new reimbursement schemes recognising a need for real-world evidence over randomised clinical trials and new standards being created specifically for apps.